Related Experiment Videos
The next generation: new chemotherapy agents for the 1990s
1Department of Nursing, Warren Grant Manguson Clinical Center, National Institutes of Health, Bethesda, MD 20892.
Seminars in Oncology Nursing
|May 1, 1992
Summary
Cancer chemotherapy has advanced significantly since the 1940s, with over 40 cytotoxic agents approved by the Food and Drug Administration (FDA). Ongoing research and clinical trials continue to introduce novel cancer treatments.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Cancer chemotherapy has seen remarkable progress since the 1940s.
- Over 40 cytotoxic agents, excluding hormones, have been approved by the Food and Drug Administration (FDA).
- Preclinical drug development and clinical trials are crucial for advancing cancer treatment options.
Purpose of the Study:
- To highlight the significant advancements in cancer chemotherapy.
- To identify newly approved or investigational cytotoxic agents.
Main Methods:
- Review of Food and Drug Administration (FDA) approved cytotoxic agents.
- Identification of drugs currently in clinical trials or recently approved.
Main Results:
- More than 40 cytotoxic chemotherapy agents have been approved by the FDA.
- New agents like idarubicin, ICRF-187, piroxantrone, all-trans-retinoic acid, fludarabine phosphate, taxol, and suramin are under investigation or recently approved.
Conclusions:
- The field of cancer chemotherapy has experienced tremendous growth.
- Continued preclinical and clinical research is essential for the development of new and effective cancer therapies.